Literature DB >> 10680807

Mitochondrial DNA mutations in complex I and tRNA genes in Parkinson's disease.

D K Simon1, R Mayeux, K Marder, N W Kowall, M F Beal, D R Johns.   

Abstract

OBJECTIVE: To identify mitochondrial DNA (mtDNA) mutations that predispose to PD.
BACKGROUND: Mitochondrial complex I activity is deficient in PD. mtDNA mutations may account for the defect, but the specific mutations have not been identified.
METHODS: Complete sequencing was performed of all mtDNA-encoded complex I and transfer RNA (tRNA) genes in 28 PD patients and 8 control subjects, as well as screening of up to 243 additional PD patients and up to 209 control subjects by restriction digests for selected mutations.
RESULTS: In the PD patients, 15 complex I missense mutations and 9 tRNA mutations were identified. After screening additional subjects, rare PD patients were found to carry complex I mutations that altered highly conserved amino acids. However, no significant differences were found in the frequencies of any mutations in PD versus control groups. The authors were unable to confirm previously reported associations of mutations at nucleotide positions (np) 4336, 5460, and 15927/8 with PD. Complex I mutations previously linked to Leber's hereditary optic neuropathy, one of which has been linked to atypical parkinsonism, were not associated with PD.
CONCLUSIONS: mtDNA mutations with a high mutational burden (present in a high percentage of mtDNA molecules in an individual) in complex I or tRNA genes do not play a major role in the risk of PD in most PD patients. Further investigations are necessary to determine if any of the rare mtDNA mutations identified in PD patients play a role in the pathogenesis of PD in those few cases.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10680807     DOI: 10.1212/wnl.54.3.703

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  31 in total

1.  Sequence analysis of two nuclear encoded subunits (10 and 51 kDa) of mitochondrial complex I in Parkinson disease.

Authors:  Eva M Grasbon-Frodl; P Mehraein
Journal:  Neurogenetics       Date:  2002-03       Impact factor: 2.660

Review 2.  Mitochondrial dysfunction and oxidative damage in Alzheimer's and Parkinson's diseases and coenzyme Q10 as a potential treatment.

Authors:  M Flint Beal
Journal:  J Bioenerg Biomembr       Date:  2004-08       Impact factor: 2.945

3.  Complex I polymorphisms, bigenomic heterogeneity, and family history in Virginians with Parkinson's disease.

Authors:  Russell H Swerdlow; Bradley Weaver; Amy Grawey; Connie Wenger; Eric Freed; Bradford B Worrall
Journal:  J Neurol Sci       Date:  2006-06-19       Impact factor: 3.181

Review 4.  The unresolved role of mitochondrial DNA in Parkinson's disease: An overview of published studies, their limitations, and future prospects.

Authors:  Amica C Müller-Nedebock; Rebecca R Brennan; Marianne Venter; Ilse S Pienaar; Francois H van der Westhuizen; Joanna L Elson; Owen A Ross; Soraya Bardien
Journal:  Neurochem Int       Date:  2019-06-21       Impact factor: 3.921

5.  Mitochondrial DNA haplogroups and mutations in children with acquired central demyelination.

Authors:  S Venkateswaran; K Zheng; M Sacchetti; D Gagne; D L Arnold; A D Sadovnick; S W Scherer; B Banwell; A Bar-Or; D K Simon
Journal:  Neurology       Date:  2011-02-02       Impact factor: 9.910

Review 6.  Mitochondrial dysfunction in the limelight of Parkinson's disease pathogenesis.

Authors:  Rebecca Banerjee; Anatoly A Starkov; M Flint Beal; Bobby Thomas
Journal:  Biochim Biophys Acta       Date:  2008-11-14

Review 7.  Mitochondria, OxPhos, and neurodegeneration: cells are not just running out of gas.

Authors:  Estela Area-Gomez; Cristina Guardia-Laguarta; Eric A Schon; Serge Przedborski
Journal:  J Clin Invest       Date:  2019-01-02       Impact factor: 14.808

Review 8.  Chronic oxidative damage together with genome repair deficiency in the neurons is a double whammy for neurodegeneration: Is damage response signaling a potential therapeutic target?

Authors:  Haibo Wang; Prakash Dharmalingam; Velmarini Vasquez; Joy Mitra; Istvan Boldogh; K S Rao; Thomas A Kent; Sankar Mitra; Muralidhar L Hegde
Journal:  Mech Ageing Dev       Date:  2016-09-20       Impact factor: 5.432

Review 9.  Current perspective of mitochondrial biology in Parkinson's disease.

Authors:  Navneet Ammal Kaidery; Bobby Thomas
Journal:  Neurochem Int       Date:  2018-03-14       Impact factor: 3.921

10.  Mitochondrial DNA polymorphisms and haplogroups in Parkinson's disease and control individuals with a similar genetic background.

Authors:  Helen Latsoudis; Cleanthe Spanaki; Grigoris Chlouverakis; Andreas Plaitakis
Journal:  J Hum Genet       Date:  2008-02-20       Impact factor: 3.172

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.